OXFORD, England, November 21, 2016 /PRNewswire/ -- Oxitec announced today the Board of the Florida Keys Mosquito Control District (FKMCD) voted to approve the investigational agreement for use of self-limiting Friendly™ mosquitoes in an effectiveness trial to fight against Aedes aegypti, the primary vector for many dangerous viruses including Zika, dengue, and chikungunya. This decision follows the November 8th approval vote by residents in Monroe County, clearly voicing their support for new solutions like Oxitec's in combatting this invasive, disease-carrying mosquito . (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) "Oxitec commends the Board of the Florida Keys Mosquito Control District in this important decision, and we remain very committed to assisting the Florida Keys in their vector control efforts," said Oxitec CEO Hadyn Parry. "Our solution has repeatedly shown it has significant potential to play a meaningful role in controlling invasive populations of Aedes aegypti. We look forward to working with the Board given the urgent need for better approaches against this harmful vector." The purpose of the Monroe County trial is to determine the efficacy of Oxitec's self-limiting mosquitoes for controlling the local population of Aedes aegypti. FKMCD and Oxitec are now working together to select a site for an investigational trial in Monroe County. The U.S. Food and Drug Administration (FDA) previously published a final finding of no significant impact (FONSI) on human health, animal health or the environment based on an environmental assessment of Oxitec's self-limiting OX513A mosquito. The FDA review team consisted of experts from the Center for Veterinary Medicine, the Centers for Disease Control and Prevention, and the Environmental Protection Agency. The FDA led an extensive review of evidence from trials of Oxitec's technology performed in urban environments since 2009, and data from numerous safety and efficacy studies, site inspections and independent experts.